Epigenomics AG
Epigenomics AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative molecular diagnostics for cancer detection. Founded in 1998, the company has established itself as a leader in the field of epigenetics, particularly with its flagship product, Epi proColon, which is designed for non-invasive colorectal cancer screening. With a strong presence in Europe and North America, Epigenomics AG is committed to advancing personalised medicine through its unique biomarker-based technologies. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. By leveraging cutting-edge research and development, Epigenomics AG continues to drive advancements in cancer diagnostics, making a meaningful impact on patient care and outcomes.
DitchCarbon Score
How does Epigenomics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Epigenomics AG's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Epigenomics AG's reported carbon emissions
Epigenomics AG, headquartered in Germany, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Epigenomics AG may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. As a result, the company does not appear to have inherited any emissions data from a parent or related organization, nor does it have any cascading targets from initiatives like the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Without specific emissions data or reduction initiatives, it is challenging to assess Epigenomics AG's climate commitments or performance within the industry context.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Epigenomics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
